Key Takeaway
Meta-analysis of 111,309 adults found mortality benefits starting at just 2,517 steps/day, with optimal doses around 8,763 steps for mortality and 7,126 steps for CVD, and additional benefits from higher stepping cadence.
Summary
This systematic review and meta-analysis published in JACC analyzed 12 prospective studies (111,309 individuals for mortality, 85,261 for CVD) to define the minimum and optimal daily step counts for reducing all-cause mortality and cardiovascular disease risk.
The key contribution of this study was identifying specific thresholds. Significant risk reductions compared with 2,000 steps/day were observed starting at just 2,517 steps for all-cause mortality and 2,735 steps for incident CVD. The optimal doses (point of maximum risk reduction with diminishing returns beyond) were approximately 8,763 steps/day for mortality and 7,126 steps/day for CVD.
Uniquely, this analysis also examined step cadence (walking speed) and found that moderate-to-high cadence was associated with additional mortality benefits independent of total step count. This finding contrasts with some earlier studies and suggests that walking speed may provide benefits above and beyond simply accumulating steps.
Methods
- Systematic review of PubMed and EMBASE from inception to October 2022
- 12 studies for all-cause mortality (111,309 individuals)
- 4 studies for incident CVD (85,261 individuals)
- 4 studies for step cadence and all-cause mortality
- Steps measured by objective devices (accelerometers/pedometers)
- Nonlinear dose-response modeling with restricted cubic splines
- Reference point set at 2,000 steps/day
Key Results
- Benefits begin at 2,517 steps/day for all-cause mortality vs. 2,000 steps
- Benefits begin at 2,735 steps/day for incident CVD vs. 2,000 steps
- Optimal dose for mortality: ~8,763 steps/day
- Optimal dose for CVD prevention: ~7,126 steps/day
- Higher step cadence associated with lower mortality risk independent of total steps
- Nonlinear dose-response: steepest risk reduction at lower step counts
- Continued benefits beyond optimal dose, but with diminishing returns
Limitations
- Observational study design limits causal inference
- Heterogeneity in follow-up duration across studies
- Limited number of studies for CVD outcomes and cadence analysis
- Most studies used single-timepoint step measurement
- Potential selection bias toward healthier, more active participants
- Could not fully account for changes in physical activity over time